한스바이오메드 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by 국민연금공단, was filed 01 Jul 2026.
한스바이오메드: what insiders have been doing
This page follows insider dealings at 한스바이오메드 as filed with DART (FSS), a company from the Health Care sector. Over the twelve months to 2 November 2026, 16 filings were filed, from 8 insiders.
On the market, 7 insiders bought (9 purchases) while 4 insiders sold (6 sales). No amount is published for 15 filings, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. On the buying side, the filings list 2 major shareholders and 1 board member among the declarants.
The most recent open-market purchase was published on 1 July 2026, 130 days ago. Between a trade and the moment it shows up on DART (FSS), the median delay is 6 days. The shorter that gap, the sooner other investors can see what insiders have done.
Across the 2,655 companies tracked on its exchange, the median is 7 filings; at 16 filings, this issuer sits above that mark. Our records for 한스바이오메드 go back to 2021, with 18 purchases and 10 sales on the open market in total.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and UCB. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Who traded when
BuySale+2 other insiders
Analyst consensus: bullish or bearish?
Analysts rate 한스바이오메드 Strong Buy (bullish).
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended September 2025 · cache
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- 191,407 sharesKRXDART:20260702000463
- 881,697 sharesKRXDART:20260701000167Canonical exit: 29 Sept 2026 (T+90)
- 481,380 sharesKRXDART:20260609000396
- 45,119 sharesKRXDART:20260605000106Canonical exit: 3 Sept 2026 (T+90)
- 257,884 sharesKRXDART:20260504000291
- 41,957 sharesKRXDART:20260409002494
- 358,820 sharesKRXDART:20260303002909Canonical exit: 6 May 2026 (T+90)
- 1,319,249 sharesKRXDART:20260126000394Canonical exit: 23 Apr 2026 (T+90)
- 1,879,153 sharesKRXDART:20260126000391
- 5,000 sharesShareKRXDART:20260122000254Canonical exit: 22 Apr 2026 (T+90)
- 1,029,265 sharesKRXDART:20260105000353Canonical exit: 11 Mar 2026 (T+90)
- 185,942 sharesKRXDART:20260105000390Canonical exit: 23 Mar 2026 (T+90)
- 171 sharesKRXDART:20251212000475Canonical exit: 11 Mar 2026 (T+90)
- 744,847 sharesKRXDART:20251211000214Canonical exit: 5 Mar 2026 (T+90)
- ●Executives0DART
- 591,183 sharesKRXDART:20251126000543
- 1,623 sharesShareKRXDART:20251031000386
- ●Executives0DART
- 58,680 sharesKRXDART:20250930000600
- 64,000 sharesShareKRXDART:20250930000597
- 158,305 sharesKRXDART:20250404003755Canonical exit: 11 Jul 2023 (T+90)
25 of 40 declarations
About 한스바이오메드
Hans Biomed is a company specializing in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative biomedical solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
